Shares of Minerva Neurosciences, Inc (NASDAQ:NERV – Get Free Report) have earned a consensus rating of “Reduce” from the four research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $10.3333.
A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research lowered Minerva Neurosciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 12th. Jefferies Financial Group raised Minerva Neurosciences from a “hold” rating to a “mixed” rating and increased their target price for the company from $7.50 to $10.00 in a report on Friday, August 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Wednesday, June 24th.
Read Our Latest Stock Report on NERV
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, equities analysts predict that Minerva Neurosciences will post -0.73 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NERV. Seven Fleet Capital Management LP acquired a new stake in Minerva Neurosciences during the 1st quarter worth $6,855,000. DV Trading LLC acquired a new stake in shares of Minerva Neurosciences in the first quarter valued at about $5,358,000. Janus Henderson Group PLC raised its position in shares of Minerva Neurosciences by 47,614.0% in the first quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock valued at $25,873,000 after buying an additional 4,285,259 shares during the last quarter. Spruce Street Capital LP purchased a new position in shares of Minerva Neurosciences in the fourth quarter worth about $6,655,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Minerva Neurosciences in the second quarter worth about $419,000. Hedge funds and other institutional investors own 34.56% of the company’s stock.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.
The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
